FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3155853644> ?p ?o ?g. }

• W3155853644 abstract "Background: Routine human papillomavirus (HPV) immunization in Belgium is currently regionally managed, with school-aged girls receiving the 9-valent HPV (9vHPV) vaccine in Flanders and Wallonia-Brussels with a national catch-up program for females only. This study will assess whether expanding these programs to gender-neutral vaccination (GNV) with the 9vHPV vaccine is a cost-effective strategy in Belgium. Methods: A validated HPV-type transmission dynamic model estimated the potential health and economic impact of regional vaccination programs, comparing GNV versus female-only vaccination (FOV) with the 9vHPV vaccine in individuals aged 11–12 years in Flanders, GNV with the 9vHPV vaccine versus FOV with the 2-valent HPV (2vHPV) vaccine in individuals aged 12–13 years in Wallonia-Brussels, and national catch-up GNV versus FOV with the 9vHPV vaccine for those aged 12–18 years. Vaccination coverage rates of 90, 50, and 50% in both males and females were used in the base cases for the three programs, respectively, and sensitivity analyses were conducted. All costs are from the third-party payer perspective, and outcome measures were reported over a 100-year time horizon. Results: GNV with the 9vHPV vaccine was projected to decrease the cumulative incidence of HPV 6/11/16/18/31/33/45/52/58-related diseases relative to FOV in both Flanders and Wallonia-Brussels. Further reductions were also projected for catch-up GNV with the 9vHPV vaccine, including reductions of 6.8% (2,256 cases) for cervical cancer, 7.1% (386 cases) and 18.8% (2,784 cases) for head and neck cancer in females and males, respectively, and 30.3% (82,103 cases) and 44.6% (102,936 cases) for genital warts in females and males, respectively. As a result, a GNV strategy would lead to reductions in HPV-related deaths. Both regional and national catch-up GNV strategies were projected to reduce cumulative HPV-related disease costs and were estimated to be cost-effective compared with FOV with incremental cost-effectiveness ratios of €8,062, €4,179, and €6,127 per quality-adjusted life-years in the three programs, respectively. Sensitivity analyses were consistent with the base cases. Conclusions: A GNV strategy with the 9vHPV vaccine can reduce the burden of HPV-related disease and is cost-effective compared with FOV for both regional vaccination programs and the national catch-up program in Belgium." @default.
• W3155853644 created "2021-04-26" @default.
• W3155853644 creator A5003969839 @default.
• W3155853644 creator A5004816651 @default.
• W3155853644 creator A5015750102 @default.
• W3155853644 creator A5047342188 @default.
• W3155853644 creator A5052803290 @default.
• W3155853644 creator A5056621237 @default.
• W3155853644 creator A5067735015 @default.
• W3155853644 creator A5090600483 @default.
• W3155853644 date "2021-04-12" @default.
• W3155853644 modified "2023-09-27" @default.
• W3155853644 title "Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium" @default.
• W3155853644 cites W1964020201 @default.
• W3155853644 cites W1965416300 @default.
• W3155853644 cites W1966287154 @default.
• W3155853644 cites W1974435872 @default.
• W3155853644 cites W1981725818 @default.
• W3155853644 cites W1986792437 @default.
• W3155853644 cites W2004693107 @default.
• W3155853644 cites W2012279313 @default.
• W3155853644 cites W2073303852 @default.
• W3155853644 cites W2078940177 @default.
• W3155853644 cites W2082352555 @default.
• W3155853644 cites W2088796145 @default.
• W3155853644 cites W2089224416 @default.
• W3155853644 cites W2089454110 @default.
• W3155853644 cites W2100770509 @default.
• W3155853644 cites W2103381545 @default.
• W3155853644 cites W2103740393 @default.
• W3155853644 cites W2113000896 @default.
• W3155853644 cites W2113311378 @default.
• W3155853644 cites W2116827928 @default.
• W3155853644 cites W2117969937 @default.
• W3155853644 cites W2123974278 @default.
• W3155853644 cites W2125058204 @default.
• W3155853644 cites W2125788249 @default.
• W3155853644 cites W2126246455 @default.
• W3155853644 cites W2126821517 @default.
• W3155853644 cites W2130505310 @default.
• W3155853644 cites W2132441113 @default.
• W3155853644 cites W2141985524 @default.
• W3155853644 cites W2142200682 @default.
• W3155853644 cites W2143158562 @default.
• W3155853644 cites W2148287035 @default.
• W3155853644 cites W2149947424 @default.
• W3155853644 cites W2273443838 @default.
• W3155853644 cites W2276701634 @default.
• W3155853644 cites W2340030325 @default.
• W3155853644 cites W2470415918 @default.
• W3155853644 cites W2472221349 @default.
• W3155853644 cites W2528304237 @default.
• W3155853644 cites W2546048036 @default.
• W3155853644 cites W2557867537 @default.
• W3155853644 cites W2561857334 @default.
• W3155853644 cites W2603870775 @default.
• W3155853644 cites W2605365014 @default.
• W3155853644 cites W2607432580 @default.
• W3155853644 cites W2734446500 @default.
• W3155853644 cites W2767593989 @default.
• W3155853644 cites W2789054712 @default.
• W3155853644 cites W2790666775 @default.
• W3155853644 cites W2795638482 @default.
• W3155853644 cites W2796316611 @default.
• W3155853644 cites W2884269596 @default.
• W3155853644 cites W2884876202 @default.
• W3155853644 cites W2889197136 @default.
• W3155853644 cites W2899489538 @default.
• W3155853644 cites W2906526078 @default.
• W3155853644 cites W2906746431 @default.
• W3155853644 cites W2910008965 @default.
• W3155853644 cites W2912326121 @default.
• W3155853644 cites W2940097644 @default.
• W3155853644 cites W2952289677 @default.
• W3155853644 cites W3026871083 @default.
• W3155853644 cites W3096780844 @default.
• W3155853644 cites W3107354568 @default.
• W3155853644 cites W4255316820 @default.
• W3155853644 cites W834221234 @default.
• W3155853644 doi "https://doi.org/10.3389/fphar.2021.628434" @default.
• W3155853644 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8072375" @default.
• W3155853644 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33912045" @default.
• W3155853644 hasPublicationYear "2021" @default.
• W3155853644 type Work @default.
• W3155853644 sameAs 3155853644 @default.
• W3155853644 citedByCount "4" @default.
• W3155853644 countsByYear W31558536442021 @default.
• W3155853644 countsByYear W31558536442022 @default.
• W3155853644 countsByYear W31558536442023 @default.
• W3155853644 crossrefType "journal-article" @default.
• W3155853644 hasAuthorship W3155853644A5003969839 @default.
• W3155853644 hasAuthorship W3155853644A5004816651 @default.
• W3155853644 hasAuthorship W3155853644A5015750102 @default.
• W3155853644 hasAuthorship W3155853644A5047342188 @default.
• W3155853644 hasAuthorship W3155853644A5052803290 @default.
• W3155853644 hasAuthorship W3155853644A5056621237 @default.
• W3155853644 hasAuthorship W3155853644A5067735015 @default.
• W3155853644 hasAuthorship W3155853644A5090600483 @default.
• W3155853644 hasBestOaLocation W31558536441 @default.
• W3155853644 hasConcept C120665830 @default.

• next